Sarepta Offers 'Attractive' Entry Point After Setbacks, Wedbush Says

MT Newswires Live12-10

Sarepta Therapeutics (SRPT) is offering an "attractive" entry point following an early summer stock sell-off due to Elevidys patient deaths, Wedbush said in a Tuesday report.

The report said the sell-off was overdone, and Elevidys could regain approval in non-ambulatory patients by early 2027.

"Sarepta is undoubtedly the best known name when it comes to Duchenne muscular dystrophy, and the recent regulatory and clinical setbacks have created an attractive entry point," said Wedbush analyst Yun Zhong.

On exon-skipping products that have generated close to $1 billion in annual sales, the report said they should continue to generate a stable revenue stream despite the recent negative ESSENCE study data and emerging competition.

"We project continued patient uptake based on a high compliance rate that SRPT has reported, comprehensive real world data supporting clinical benefit, and favorable KOL feedback," the analyst said. KOL refers to Key Opinion Leaders.

Wedbush initiated coverage of the stock with an outperform rating and a price target of $32 per share.

Price: 22.22, Change: +0.36, Percent Change: +1.65

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2590432314?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-10 01:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2590432314","market":"sg","top_or_hot":-1,"title":"Sarepta Offers 'Attractive' Entry Point After Setbacks, Wedbush Says","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/SRPT\">Sarepta Therapeutics</a> (SRPT) is offering an \"attractive\" entry point following an early summer stock sell-off due to Elevidys patient deaths, Wedbush said in a Tuesday report.</p><p>The report said the sell-off was overdone, and Elevidys could regain approval in non-ambulatory patients by early 2027.</p><p>\"Sarepta is undoubtedly the best known name when it comes to Duchenne muscular dystrophy, and the recent regulatory and clinical setbacks have created an attractive entry point,\" said Wedbush analyst Yun Zhong.</p><p>On exon-skipping products that have generated close to $1 billion in annual sales, the report said they should continue to generate a stable revenue stream despite the recent negative ESSENCE study data and emerging competition.</p><p>\"We project continued patient uptake based on a high compliance rate that SRPT has reported, comprehensive real world data supporting clinical benefit, and favorable KOL feedback,\" the analyst said. KOL refers to Key Opinion Leaders.</p><p>Wedbush initiated coverage of the stock with an outperform rating and a price target of $32 per share.</p><p>Price: 22.22, Change: +0.36, Percent Change: +1.65</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sarepta Offers 'Attractive' Entry Point After Setbacks, Wedbush Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSarepta Offers 'Attractive' Entry Point After Setbacks, Wedbush Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-12-10 01:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/SRPT\">Sarepta Therapeutics</a> (SRPT) is offering an \"attractive\" entry point following an early summer stock sell-off due to Elevidys patient deaths, Wedbush said in a Tuesday report.</p><p>The report said the sell-off was overdone, and Elevidys could regain approval in non-ambulatory patients by early 2027.</p><p>\"Sarepta is undoubtedly the best known name when it comes to Duchenne muscular dystrophy, and the recent regulatory and clinical setbacks have created an attractive entry point,\" said Wedbush analyst Yun Zhong.</p><p>On exon-skipping products that have generated close to $1 billion in annual sales, the report said they should continue to generate a stable revenue stream despite the recent negative ESSENCE study data and emerging competition.</p><p>\"We project continued patient uptake based on a high compliance rate that SRPT has reported, comprehensive real world data supporting clinical benefit, and favorable KOL feedback,\" the analyst said. KOL refers to Key Opinion Leaders.</p><p>Wedbush initiated coverage of the stock with an outperform rating and a price target of $32 per share.</p><p>Price: 22.22, Change: +0.36, Percent Change: +1.65</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BFTCPJ56.SGD","symbol_name":"Janus Henderson Global Life Sciences A Acc SGD","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2590432314","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2590432314","pubTimestamp":1765300243,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Sarepta Therapeutics  is offering an \"attractive\" entry point following an early summer stock sell-off due to Elevidys patient deaths, Wedbush said in a Tuesday report.The report said the sell-off was overdone, and Elevidys could regain approval in non-ambulatory patients by early 2027.\"Sarepta is undoubtedly the best known name when it comes to Duchenne muscular dystrophy, and the recent regulatory and clinical setbacks have created an attractive entry point,\" said Wedbush analyst Yun Zhong.On exon-skipping products that have generated close to $1 billion in annual sales, the report said they should continue to generate a stable revenue stream despite the recent negative ESSENCE study data and emerging competition.\"We project continued patient uptake based on a high compliance rate that SRPT has reported, comprehensive real world data supporting clinical benefit, and favorable KOL feedback,\" the analyst said. KOL refers to Key Opinion Leaders.Wedbush initiated coverage of the stock wi","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","BK4585":"ETF&股票定投概念","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","BK4139":"生物科技","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","SRPT":"Sarepta Therapeutics"},"translate_title":"韦德布什表示，Sarepta在遭遇挫折后提供了“有吸引力”的切入点","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SRPT":1},"content_text":"Sarepta Therapeutics (SRPT) is offering an \"attractive\" entry point following an early summer stock sell-off due to Elevidys patient deaths, Wedbush said in a Tuesday report.The report said the sell-off was overdone, and Elevidys could regain approval in non-ambulatory patients by early 2027.\"Sarepta is undoubtedly the best known name when it comes to Duchenne muscular dystrophy, and the recent regulatory and clinical setbacks have created an attractive entry point,\" said Wedbush analyst Yun Zhong.On exon-skipping products that have generated close to $1 billion in annual sales, the report said they should continue to generate a stable revenue stream despite the recent negative ESSENCE study data and emerging competition.\"We project continued patient uptake based on a high compliance rate that SRPT has reported, comprehensive real world data supporting clinical benefit, and favorable KOL feedback,\" the analyst said. KOL refers to Key Opinion Leaders.Wedbush initiated coverage of the stock with an outperform rating and a price target of $32 per share.Price: 22.22, Change: +0.36, Percent Change: +1.65","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2590432314","isCrawlerRequest":true}